ARWR
ArrowheadCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The constructive case remains execution-led rather than purely speculative: REDEMPLO launch metrics were strong for an early orphan rollout, ex-U.S. regulatory progress is real, and fresh company data on ARO-INHBE gives Arrowhead another visible pipeline leg beyond triglyceride disease [#SEC-8K-2026-05-07] [#IR-2026-05-27].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Biopharma cash burn remains meaningful, so weak commercialization or delayed milestones could refocus investors on balance-sheet duration.
Momentum
61
Value
49
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $84.00 · Bull $102.00 · Bear $62.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $101.60
Why
Momentum61 · Δ7d +34.7
Value49 · Δ7d -0.2
Sentiment41 · Δ7d -4.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
61
26% active weight
Current posture
7d trendFlat
Δ7d
+34.7
Δ21d
+4.5
Value
49
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.2
Sentiment
41
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.9
Δ21d
+7.9
Why this grade
Composite grade C. Momentum 61.1 / Value 48.8 / Sentiment 41.3
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$12.49B
Beta
1.22
Shares Out
140.86M
P/E (TTM) · Derived
-8870.0
P/S (TTM)
10.46
P/FCF (TTM)
55.30
Rev YoY
-86.4%
EPS YoY
-133.8%
Gross Margin
+95.9%
Op Margin
+11.9%
Net Debt
-$185.69M
Current Ratio
6.23
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology